ConcertAI is a leading healthcare technology company specializing in real-world data (RWD) solutions for oncology clinical trials, patient solutions, and research biopharma platforms.

ConcertAI

Atropos Health provides personalized real-world evidence in healthcare. The solutions include health system analytics, precision medicine technology, and life sciences research support, focusing on evidence generation tools.

Atropos Health

Osmind is a technology platform for mental health treatment and research, focusing on evidence-based medicine and outcomes tracking for patients with moderate to severe mental health conditions.

Osmind

The fastest growing AI-powered SaaS data company in healthcare. 

AllianceBernstein

Declaration Partners

SymphonyAI

Maverick Ventures

Sixth Street Partners

In this captivating episode of the ConcertAI Podcast, we dive deep with Jennifer R. Rider, ScD, MPH, a renowned cancer epidemiologist. Jennifer shares her journey from academia to the dynamic world of real-world data (RWD) and its vital role in oncology research. We explore how RWD is transforming the landscape of prostate cancer studies and its increasing importance in regulatory decision-making.

Discover how the field of RWD has evolved and its pivotal contributions to the development and application of groundbreaking oncology treatments. Jennifer's insights into the integration of RWD in clinical trials and its potential to shape future cancer therapies are truly enlightening.

Tune in to gain a deeper understanding of the impact and possibilities of real-world data in cancer research and treatment.

Check out the full episode now! Don't forget to subscribe for more insightful discussions on the latest trends in healthcare technology and research.

Listen on Apple Podcasts: https://lnkd.in/gYGYkczc

Listen on Spotify: https://lnkd.in/gjVYeccN

#ConcertAIPodcast #Oncology #RealWorldData #CancerResearch #HealthcareInnovation

We are happy to announce that Dr. Jennifer R. Rider, ScD, MPH, an esteemed cancer epidemiologist, is joining ConcertAI to lead our Real-World Evidence Services. With over two decades of experience, Dr. Rider will spearhead regulatory applications of Real-World Data, impacting oncology trials, breakthrough designations, and regulatory registries.

Boasting an impressive academic background from top institutions like Harvard and Boston University, Dr. Rider returns to ConcertAI, where her oncology RWE journey began in 2020. In her expanded role, she'll also lead the Oncology RWE Leadership Forum, fostering collaboration among industry, academia, and regulatory leaders.

Read the full announcement: https://lnkd.in/gkeZ6f_u 

#RealWorldEvidence #medicalinnovation #leadership


SCOPE 2024 is less than two weeks away! Join us in booth 422 to learn more about our work in oncology clinical trials and our real-world data. At the forefront is our Digital Trial Solution (DTS), a Gen and Predictive AI-enabled Software-as-a-Service suite, which is revolutionizing clinical trial management. DTS harnesses the power of over 8 million records and AI for Study Optimization, enhancing study designs to unprecedented levels of efficiency and effectiveness.

Schedule a meeting with our team: https://lnkd.in/e2eCza7z

#SCOPE2024 #SCOPESummit #clinicaltrials  #healthcareequality  #oncology 

Season Two of The ConcertAI Podcast starts next week! Join us as we explore exciting topics like clinical trial design, multimodal data, and the  latest in healthcare technology.
 
Discover insights on clinical trial advancements and the impact of AI and causal inference in our discussions.
 
Tune in to Apple Podcasts or Spotify for engaging episodes that shape the future of healthcare. Listen now for your dose of innovation and expert analysis.
 
Apple Podcasts: https://lnkd.in/d-MbqAFj
 
Spotify: https://lnkd.in/dfGgZ3bs
 
#podcast #healthcareinnovation #clinicaltrials #RWE #realworldevidence 

"Real-world Homologous Recombination Repair Mutation (HRRm) Testing Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Olaparib in the United States" showcases a groundbreaking use of ConcertAI's Oncology Dataset, presented at the 2024 ASCO Genitourinary Cancers Symposium. Funded by Merck and AstraZeneca, this study offers crucial insights into mCRPC treatment. 

By leveraging ConcertAI's comprehensive Oncology Dataset, the research provides an unparalleled analysis of HRRm testing patterns in mCRPC patients treated with olaparib. This approach highlights the importance of data-driven insights in understanding treatment outcomes and the potential for enhancing patient care through timely genetic testing. 

Join us at the ASCO GU Symposium's Poster Session A: Prostate Cancer to explore how our Oncology Dataset is revolutionizing the landscape of cancer research. This collaborative effort, supported by industry leaders like Merck and AstraZeneca underscores our dedication to harnessing data for advancing cancer treatment. 

Learn more: https://lnkd.in/eHyDwVxv

#ASCO #GU24 #CancerResearch #OlaparibInnovation

Francesca Coutinho

Metric
Company Name	ConcertAI	Atropos Health	Osmind
Symbol
MSH ID	COM:CONCERTAI	COM:ATROPOSHEALTH	ORG:OSMIND
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare Technology	Health Technology	Mental Health Technology
Country	US	US	US
Stage	Series C	Series B	Series B
Employee Count	842
Website	concertai.com	atroposhealth.com	osmind.org
LinkedIn	concertai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	14.91K	3.29K	60.54K
Web Traffic Growth	0.16	-0.85	-0.02
Valuation
Raised Capital	150M	33M	40M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CONCERTAI

ConcertAI

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue